| 國立臺灣大學 |
2014 |
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response
|
de Azambuja, Evandro; Holmes, Andrew P.; Piccart-Gebhart, Martine; Holmes, Eileen; Di Cosimo, Serena; Swaby, Ramona F.; Untch, Michael; Jackisch, Christian; Lang, Istvan; Smith, Ian; Boyle, Frances; Xu, Binghe; Barrios, Carlos H.; Perez, Edith A.; Azim, Hatem A., Jr.; Kim, Sung-Bae; Kuemmel, Sherko; Huang, Chiun-Sheng; Vuylsteke, Peter; Hsieh, Ruey-Kuen; Gorbunova, Vera; Eniu, Alexandru; Dreosti, Lydia; Tavartkiladze, Natalia; Gelber, Richard D.; Eidtmann, Holger; Baselga, Jose; 黃俊升 |
